Skip to main content Deutsch


Usevalad Ustsinau
Ing. Usevalad Ustsinau, MSc

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: PHD Student

ORCID: 0000-0002-1464-9383
T +43 1 40400-58736


Energy Metabolism; Multimodal Imaging; Obesity; Positron-Emission Tomography

Research group(s)

Research interests

My primary focus is centered around the evaluation of metabolic disorders. The role of energy metabolism in the development of various ailments, such as obesity, Type 2 Diabetes Mellitus, and Non-alcoholic Fatty Liver Disease (NAFLD), has been recently well-established. In this regard, I am interested in exploring the use of functional imaging techniques in nuclear medicine to detect variations in tracer kinetics in both clinical and preclinical models.

Techniques, methods & infrastructure

My expertise lies in managing the entire preclinical PET imaging process from start to finish. This includes producing radiotracers (labeling with 18F), handling animals safely with a FELASA certificate, establishing hybrid PET imaging protocols, and processing the resulting signal and images using software such as Pmod, Hermes, ITK Snap, Carimas and others.

Selected publications

  1. Ustsinau, U. et al. (2023) ‘Novel approach using [18F]FTHA-PET and de novo synthesized VLDL for assessment of FFA metabolism in a rat model of diet induced NAFLD’, Clinical Nutrition, 42(10), pp. 1839–1848. Available at:
  2. Ustsinau, U. et al. (2024) ‘A Fully Automated Synthesis of 14-(R,S)-[18F]fluoro-6-thia-heptadecanoic Acid ([18F]FTHA) on the Elixys Radiosynthesizer’, Pharmaceuticals, 17(3), p. 318. Available at:
  3. Ustsinau, U. et al. (2024) ‘A PET/MRI study on the effect of obesity and NAFLD on hepatic [18F]FDG uptake’, European Journal of Radiology, p. 111552. Available at: